Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 2/20 | 0.44 |
| ▸ | CPA3 | P15088 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248704 | 1.00 | CYP1A2 (0.50) | CYP1A2PPARGPPARASRRALPI | |
| SCHEMBL27516881 | 0.86 | ATM (0.49) | MAPTALDH1A1MEN1POLBCYP2C9 | |
| SCHEMBL6694352 | 0.86 | ACE (0.42) | MEN1KMT2ANPC1RAB9A | |
| Tyrosine SCHEMBL2672368 | 0.85 | SLC7A5 (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7452871 | 0.83 | CYP1A2 (0.47) | CYP1A2SRRALPIPKMPTGS1 | |
| SCHEMBL7452874 | 0.83 | CYP1A2 (0.47) | CYP1A2SRRALPIPKMPTGS1 | |
| SCHEMBL7424670 | 0.81 | CYP1A2 (0.46) | CYP1A2PPARGPPARASRRALPI | |
| SCHEMBL7424666 | 0.81 | CYP1A2 (0.46) | CYP1A2PPARGPPARASRRALPI | |
| Hydrochloric Acid SCHEMBL11438414 | 0.81 | ALPI (0.47) | CYP1A2PPARGPPARASRRALPI | |
| SCHEMBL7552899 | 0.80 | SRR (0.46) | CYP1A2PPARGPPARASRRALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107012179-A | The enzymatic conversion preparation method of 3,4 dimethoxy L phenylalanines | 南京医科大学 | 2017-08-04 | — | — | CN | claimed |
| US-3991077-A | SOLVENT | AJINOMOTO CO., INC. (JA) | 1976-11-09 | — | — | US | claimed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250325644-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | ELICIO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4627079-A2 | THERMOSTABLE BINDING SCAFFOLDS | Nectagen, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12370245-B2 | ALK polypeptides and methods of use thereof | Elicio Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2004050688-A1 | NOVEL χ-CONOTOXIN PEPTIDES (-II) | XENOME LTD (AU) | 2004-06-17 | — | — | WO | disclosed |
| EP-1416934-A2 | PROTEIN KINASE INHIBITORS COMPRISING ATP MIMETICS CONJUGATED TO PEPTIDES OR PEPTIDOMIMETICS | Peptor Ltd. (IL) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003010281-A2 | PROTEIN KINASE INHIBITORS COMPRISING ATP MIMETICS CONJUGATED TO PEPTIDES OR PEPTIDOMIMETICS | PEPTOR LTD. (IL) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002048312-A2 | BACKBONE CYCLIZED INHIBITORS OF HEAT SHOCK PROTEINS | PEPTOR LTD. (IL) | 2002-06-20 | — | — | WO | disclosed |
| EP-0644772-A4 | OPIOID PEPTIDES. | BIOMEASURE INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0644772-A1 | OPIOID PEPTIDES | BIOMEASURE, INC. (US) | 1995-03-29 | — | — | EP | disclosed |
| WO-1994011018-A1 | OPIOID PEPTIDES | BIOMEASURE, INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0351382-A2 | Process for the synthesis of optically active aminoacids | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1990-01-17 | — | — | EP | disclosed |
| EP-0000745-B1 | SALT OF AN OPTICALLY ACTIVE ISOMER OF PHENYLGLYCINE AND AN OPTICALLY ACTIVE ISOMER OF 2-AMINO BUTANOL AND PROCESS FOR ITS PREPARATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | CYP1A2 2291/4885PPARG 1908/4885PPARA 2269/4885 |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | CYP1A2 4798/4885PPARG 4347/4885PPARA 4357/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | CYP1A2 2494/4885PPARG 3551/4885PPARA 3874/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | CYP1A2 2591/4885PPARG 3112/4885PPARA 3238/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | CYP1A2 3129/4885PPARG 4731/4885PPARA 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.